Evidence map›Paper›PMID 35851753›Full record

ArticleInternational journal of rheumatic diseases2022

Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort.

Hakan Apaydin, Abdulsamet Erden, Serdar Can Güven, Berkan Armağan, Hatice Ecem Konak, Bünyamin Polat, Yağnur Afşin, Merve Kaygisiz, Ahmet Omma, Orhan Kucuksahin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Vogt-Koyanagi-Harada Disease and COVID.Journal of clinical medicine · 2023
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Hakan ApaydinClinical Rheumatology, Ankara City Hospital, Cankaya, Turkey.ORCID https://orcid.org/0000-0001-7219-1457
Abdulsamet ErdenDivision of Rheumatology, Department of Internal Medicine, Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Türkiye.ORCID https://orcid.org/0000-0002-8084-2018
Serdar Can GüvenClinical Rheumatology, Ankara City Hospital, Cankaya, Turkey.ORCID https://orcid.org/0000-0003-1965-9756
Berkan ArmağanClinical Rheumatology, Ankara City Hospital, Cankaya, Turkey.ORCID https://orcid.org/0000-0003-4409-059X
Hatice Ecem KonakClinical Rheumatology, Ankara City Hospital, Cankaya, Turkey.ORCID https://orcid.org/0000-0002-9218-8965
Bünyamin PolatClinical Rheumatology, Ankara City Hospital, Cankaya, Turkey.ORCID https://orcid.org/0000-0003-4972-8142
Yağnur AfşinInternal Medicine, Ankara City Hospital, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-3444-4892
Merve KaygisizInternal Medicine, Ankara City Hospital, Ankara, Türkiye.ORCID https://orcid.org/0000-0001-7391-5541
Ahmet OmmaClinical Rheumatology, University of Health Sciences, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-2582-7445
Orhan KucuksahinDivision of Rheumatology, Department of Internal Medicine, Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Türkiye.ORCID https://orcid.org/0000-0003-4530-2304
Çankaya University · TRAnkara Yıldırım Beyazıt University · TRMemorial Ankara Hospital · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimVaccination represents a cornerstone in mastering the coronavirus disease 2019 (COVID-19) pandemic. There is a paucity of data regarding the safety of COVID-19 vaccines in patients with rheumatic diseases such as Behçet syndrome (BS). The present study aimed to investigate the side-effects and post-vaccine disease exacerbation rates of COVID-19 vaccines in a BS cohort.

methodsWe retrospectively evaluated 450 BS patients followed in our clinic who met the criteria of the International Study Group. COVID-19 vaccination status, type of vaccine received (Pfizer-BioNTech vs CoronaVac), post-vaccine side-effects and exacerbations were evaluated by interviewing patients over the phone or face to face. Behçet's Disease Current Activity Form (BDCAF) scores were calculated for BS symptoms before and after vaccination.

resultsIn all, 287 patients received at least one dose of the COVID-19 vaccine. Of the total number of COVID-19 vaccines (n = 639), 379 (59%) were Pfizer-BioNTech vaccines and 257 (41%) were CoronaVac vaccines. The number of side-effects after first, second, third and fourth vaccine doses were 151 (52.6%), 135 (49.4%), 29 (42.6%), and 3 (30%), respectively. BS exacerbation after first, second, third, and fourth vaccine doses were 151 (52.6%), 135 (49.4%), 16 (23.5%), and 3 (30%), respectively. Injection site pain/swelling was the most common side-effect at all vaccine doses followed by fatigue and arthralgia.

conclusionCOVID-19 vaccines are well tolerated in patients with BS, and more side-effects develop after mRNA vaccines. Regardless of the vaccine type, exacerbations after the COVID-19 vaccine are common, predominantly mucocutaneous and articular involvement, and exacerbations in the form of other organ involvement are rare.

Indexed as

Behcet SyndromeCOVID-19COVID-19 VaccinesBNT162 VaccineDisease ProgressionHumansRetrospective StudiesVaccinationVaccines, InactivatedBNT162 VaccineCOVID-19 Vaccinessinovac COVID-19 vaccineVaccines, InactivatedBehçet syndromecoronavirusCOVID-19inactivemRNAvaccination

Identifiers

PMID35851753
PMCPMC9349705
OpenAlexW4285801563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.